FDA clears IND for Lyndra's LYN-014 for weekly treatment of opioid use disorder May 7, 2021 No Comments
InterveXion reports phase II data on IXT-m200 in methamphetamine use disorder April 20, 2021 No Comments
First subjects dosed in study comparing nasal nalmefene with nasal naloxone April 6, 2021 No Comments
Primary safety endpoint met in phase Ib/II study of BXCL-501 to treat opioid withdrawal symptoms April 1, 2021 No Comments
RSS